SEGMENT INFORMATION (Tables)

9 Months Ended

Sep. 30, 2023

Segment Reporting [Abstract]

Schedule of segment revenues and profit

Segment revenues and profits were as follows:

	Three Months Ended September 30,				Nine Months Ended September 30,
(in millions)	2023		2022		2023		2022
Revenues:
Salix	$	614	$	544	$	1,667	$	1,509
International	275		250		781		727
Solta Medical	83		72		244		201
Diversified	259		238		684		722
Bausch + Lomb	1,007		942		2,973		2,772
	$	2,238	$	2,046	$	6,349	$	5,931
Segment profits:
Salix	$	429	$	391	$	1,129	$	1,067
International	91		85		236		242
Solta Medical	33		33		114		88
Diversified	172		151		417		450
Bausch + Lomb	244		226		699		640
	969		886		2,595		2,487
Corporate	(222)		(218)		(703)		(614)
Amortization of intangible assets	(253)		(290)		(795)		(902)
Goodwill impairments	(402)		(119)		(402)		(202)
Asset impairments	(4)		(1)		(54)		(15)
Restructuring, integration, separation and IPO costs	(14)		(10)		(40)		(58)
Other expense, net	(60)		(4)		—		(6)
Operating income	14		244		601		690
Interest income	6		3		19		8
Interest expense	(339)		(385)		(965)		(1,157)
Gain on extinguishment of debt	—		570		—		683
Foreign exchange and other	(7)		7		(38)		4
(Loss) income before income taxes	$	(326)	$	439	$	(383)	$	228

Schedule of revenues by segment and product category

Revenues by segment and product category were as follows:

(in millions)	Salix		International		Solta Medical		Diversified		Bausch + Lomb		Total
	Three Months Ended September 30, 2023
Pharmaceuticals	$	613	$	63	$	—	$	210	$	113	$	999
Devices	—		—		83		—		411		494
OTC	—		47		—		2		408		457
Branded and Other Generics	—		151		—		40		72		263
Other revenues	1		14		—		7		3		25
	$	614	$	275	$	83	$	259	$	1,007	$	2,238
	Three Months Ended September 30, 2022
Pharmaceuticals	$	543	$	68	$	—	$	206	$	118	$	935
Devices	—		—		72		—		390		462
OTC	—		39		—		2		364		405
Branded and Other Generics	—		131		—		24		65		220
Other revenues	1		12		—		6		5		24
	$	544	$	250	$	72	$	238	$	942	$	2,046
	Nine Months Ended September 30, 2023
Pharmaceuticals	$	1,668	$	178	$	—	$	567	$	355	$	2,768
Devices	—		—		244		—		1,225		1,469
OTC	—		125		—		6		1,182		1,313
Branded and Other Generics	—		438		—		92		201		731
Other revenues	(1)		40		—		19		10		68
	$	1,667	$	781	$	244	$	684	$	2,973	$	6,349
	Nine Months Ended September 30, 2022
Pharmaceuticals	$	1,508	$	192	$	—	$	608	$	339	$	2,647
Devices	—		—		201		—		1,169		1,370
OTC	—		112		—		5		1,066		1,183
Branded and Other Generics	—		385		—		91		181		657
Other revenues	1		38		—		18		17		74
	$	1,509	$	727	$	201	$	722	$	2,772	$	5,931

Schedule of revenue attributed to a geographic region

Revenues are attributed to a geographic region based on the location of the customer and were as follows:

	Three Months Ended September 30,				Nine Months Ended September 30,
(in millions)	2023		2022		2023		2022
U.S. and Puerto Rico	$	1,358	$	1,219	$	3,738	$	3,524
China	113		116		315		293
Canada	92		92		268		258
Poland	82		65		232		204
Mexico	90		70		234		200
France	49		44		169		159
Japan	47		47		145		148
Russia	35		59		105		122
Germany	34		32		119		112
United Kingdom	32		28		92		85
South Korea	24		19		69		58
Spain	20		17		67		61
Italy	20		17		64		60
Other	242		221		732		647
	$	2,238	$	2,046	$	6,349	$	5,931

Schedule of customers that accounted for 10% or more of total revenue

Customers that accounted for 10% or more of total revenues were as follows:

	Nine Months Ended September 30,
	2023	2022
AmerisourceBergen Corporation	19%	16%
McKesson Corporation (including McKesson Specialty)	15%	13%
Cardinal Health, Inc.	13%	11%